Mene Pangalos is Executive Vice-President, BioPharmaceuticals R&D


A member of the company’s Senior Executive team, Mene has overall responsibility for the company’s pharmaceutical discovery research and early development activities.

Since joining AstraZeneca in 2010, Mene has been instrumental in rebuilding the company’s commitment to science and scientific excellence. He has led the transformation of R&D productivity; driven deeper collaborations with academic, biotech and peer organisations; pioneered programmes to promote Open Innovation and fostered a science driven culture that rewards great science and truth-seeking behaviours.

Mene retains an active interest in neurodegenerative disease and neuropharmacology and continues to mentor post docs and PhD students.

Mene has published more than 140 peer-reviewed articles in scientific journals and is an internationally renowned expert in neuroscience and drug discovery. He is a leading figure in UK science, serving on several Boards including the Medical Research Council, the National Centre for Universities and Business Council, the Ministers and Industry Strategy Group and the Cambridge Biomedical Campus Strategy Board.

Mene is also overseeing the creation of AstraZeneca’s new £330 million research centre in Cambridge – a state of the art facility designed to stimulate collaborative scientific innovation and which will play an important role in the future success of the UK life science industry.

Our commitment is clear – fostering a culture that rewards pioneering science and asks the ‘killer’ questions. It’s how we push the boundaries of what’s possible.

Menelas Pangalos

CURRENT ROLE

Executive Vice-President, BioPharmaceuticals R&D

TRANSFORMING R&D

Developed and implemented the “5R” framework

CREATING NEW R&D CENTRE

Overseeing the creation of AstraZeneca’s new £330 million research centre in Cambridge

PIONEERING INITIATIVES

In Nature Reviews Drug Discovery describing the pioneering drug repositioning initiatives in IMED

FOLLOWING THE SCIENCE

Ensuring the continued development of our olaparib programme in 2012 and seeing it through to approval in 2014

  Featured publications
 

GABA

The GABAB2 subunit is essential for G protein coupling of the GABAB receptor heterodimer.

Robbins MJ, Calver AR, Fillipov AK, Couve A, Moss SJ and Pangalos MN. J. Neuroscience (2001) 21: 8043-8052.
http://www.jneurosci.org/content/21/20/8043.full.pdf

A role for cAMP dependent protein kinase phosphorylation in facilitating GABAB receptor effector coupling Nature Neuroscience (2002)

Couve A, Thomas P, Calver A, Hirst WD, Pangalos MN, Walsh FW, Smart T and Moss SJ. 5: 1-10.
http://www.nature.com/neuro/journal/v5/n5/full/nn833.html

Phospho-dependent functional modulation of GABAB receptors by the metabolic sensor AMP-dependent protein kinase. Neuron.

Kuramoto N, Wilkins M, Fairfax B, Revilla-Sanchez R, Tamaki K, Couve A, Calver AR, Horvath Z, Freeman K, Carling D, Huang L, Cooper E, Gonlazes C, Cooper E, Smart TG, Pangalos MN, Moss SJ. (2007) 53:233-247.
http://www.cell.com/neuron/abstract/S0896-6273(06)01020-8

Prolonged activation of NMDA receptors induces dephosphorylation and degradation of GABAB receptors.

Terunuma M, Vargas KJ, Wilkins ME, Ramirez OA, Pangalos MN, Smart TG, Moss SJ and Couve A. PNAS (2010) 107(31):13918-23.
http://www.pnas.org/content/107/31/13918.full

Postsynaptic GABAB Receptor Activity Regulates Excitatory Neuronal Architecture and Spatial Memory.

Terunuma M, Revilla-Sanchez R, Quadros IM, Deng Q, Deeb TZ, Lumb M, Sicinski P, Haydon PG, Pangalos MN and Moss SJ. J Neurosci (2014) 34:804-816.
http://www.jneurosci.org/content/34/3/804.full.pdf

Alzheimer’s disease

Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer’s disease.

Jacobsen JS, Wu C-C, Redwine JM, Comery TA, Arias R, Bowlby M, Martone R, Morrison JH, Pangalos MN, Reinhart PH and  Bloom FE. PNAS (2006) 103: 5161-5166.
http://www.pnas.org/content/103/13/516

Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade.

Jacobsen SJ, Comery TA, Marton RL, Elkodah H, Crandall DL, Oganesian A, Aschmies S, Kirksey Y, Gonzalez C, Xu J, Zaleska MM, Das I, Arias RL, Bard J, Riddell D, Gardell SJ, Abou-Gharbia M, Robichaud A, Magolda R, Vlasuk GP, Bjornsson T, Reinhart PH, Pangalos MN. PNAS (2008) 105: 8754-8759.
http://www.pnas.org/content/105/25/8754.ful

Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels.

Riddell DR, Kirksey Y, Hu Y, Warwick HK, Li Zhutting, Zhou H, Jacobsen JS, Pangalos MN and Reinhart PH and J Neurosci. (2008) 28(45):11445-11453.
http://www.jneurosci.org/content/28/45/11445.full.pdf

Amyloid based treatments for Alzheimer’s disease. In The Biology of Alzheimer’s Disease, edited by Holtzman D, Mandelkow E and Selkoe D

Basi G, Pangalos MN and Schenk D.  (2012) 423-454.


R&D Productivity

What Is to Be Done? “Translational Neuroscience: Toward New Therapies” Strüngmann Forum Reports Series

Holtzman DM, Nikolich K, Pangalos MN, Broich K, Ip NY, Koo EH, Koroshetz WJ, Masliah E, Mucke L, Nicotera P, Schnaars M, Spillantini MG. Neurodegenerative Diseases;  ed. J. Lupp. Cambridge, MIT Press (2015).

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nature Drug Discovery

Cooke D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G and Pangalos MN. (2014) 13, 419–431.
http://www.nature.com/nrd/journal/v13/n6/full/nrd4309.html

Pioneering Government-Sponsored, Collaborative Drug Repositioning Initiatives: Progress and Learning. Nature Reviews Drug Discovery

Frail D, Wegner C, Sanganee H, Brady M, Escott J, Pangalos MN, Holt A and Watkins C. (2015) in press.

Honours

Fellow of the Academy of Medical Sciences

Honours

Fellow of the Royal Society of Biology

Award

Scrip Award – MRC-AZ Open Innovation Translational Medicine Alliance

Our people

Our people share a common purpose: to push the boundaries of science to deliver life-changing medicines.

What science can do

Stories from our people and our partners reveal the passion, energy and knowledge that enable us to put science at the heart of everything we do.

Our company

We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.